Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Aspacytarabine hydrochloride by Ayala Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
Aspacytarabine hydrochloride is under clinical development by Ayala Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData,...
Aspacytarabine hydrochloride by Ayala Pharmaceuticals for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Aspacytarabine hydrochloride is under clinical development by Ayala Pharmaceuticals and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...
Aspacytarabine hydrochloride by Ayala Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Aspacytarabine hydrochloride is under clinical development by Ayala Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According...
Aspacytarabine hydrochloride by Ayala Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Aspacytarabine hydrochloride is under clinical development by Ayala Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According...